Baricitinib(CAS NO.:1187594-09-7)
Basic information
Product Name: Baricitinib
Synonyms:
CAS: 1187594-09-7
MF: C16H17N7O2S
MW: 371.42
Chemical Properties
Melting point: 212-215°C
Density: 1.56
storage temp.: -20°C
Solubility: Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).
Pka: 11.66±0.50(Predicted)
Form: solid
Color: White or off-white
Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
InChI: InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
InChIKey: XUZMWHLSFXCVMG-UHFFFAOYSA-N
SMILES: N1(S(CC)(=O)=O)CC(N2C=C(C3N=CN=C4NC=CC4=3)C=N2)(CC#N)C1
Product Introduction
Here are some detailed application areas:
1. Treatment of Rheumatoid Arthritis (RA): Baricitinib is primarily used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults, especially for patients who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). It can be used as monotherapy or in combination with methotrexate.
2. Treatment of Alopecia Areata (AA): Baricitinib is also used to treat alopecia areata (AA), and it can alleviate pain, stiffness, and swelling in adults with rheumatoid arthritis when other treatments are ineffective. It also helps to slow down bone and joint damage.
3. Treatment of Other Autoimmune Diseases: The efficacy of baricitinib in treating psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus, and other diseases is currently in Phase II clinical studies.
4. COVID-19 Treatment: During the COVID-19 pandemic, baricitinib has also been studied for the treatment of COVID-19 patients, especially those with severe conditions requiring mechanical ventilation.
5. Scientific Research and Chemical Reagent Field: Baricitinib is also used in scientific research as a selective inhibitor of JAK1 and JAK2, and it is used to study the role of the JAK-STAT signaling pathway in immune responses and inflammation.
6. Mechanism of Action: As a selective JAK1 and JAK2 inhibitor, baricitinib reduces autoimmune responses and inflammation by inhibiting the activity of JAK proteins, which modulate the signal transduction of various cytokines and growth factors.
7. Clinical Studies: Baricitinib has shown potential efficacy in the treatment of rheumatoid arthritis and other autoimmune diseases in multiple clinical studies, providing a scientific basis for future treatments.
In summary, baricitinib not only has a clear application in the treatment of rheumatoid arthritis but also shows potential in the treatment of other autoimmune diseases and in scientific research.